Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Competitive TresibaⓇ label across all three triad markets Slide 68 Japan Duration of action up to 26 hours in Japanese patients • Four times lower day-to-day variability vs insulin glargine • Non-inferior HbA1c reduction Numerically greater FPG reduction Profile Efficacy Safety • Convenience • TresibaⓇ label characteristics in triad markets US Half-life of 25 hours and duration of action of at least 42 hours Day to day variability of 20% Non-inferior HbA1c reduction Numerically greater FPG reduction Numerically lower insulin dose¹ Overall safety consistent with insulin Hypoglycaemia rates for TresibaⓇ, but not comparator Injection any time of day Up to 80 and 160 units per injection 1 Observed in majority of the trials Europe • . • Duration of action beyond 42 hours Four times lower day-to-day variability vs insulin glargine • Non-inferior HbA1c reduction • • Numerically greater FPG reduction Overall safety consistent with insulin • Lower rate of overall and nocturnal hypoglycaemia • • Adjusting injection time when needed Up to 80 and 160 units per injection • • • changing diabetes® Overall safety consistent with insulin • Lower rate of nocturnal hypoglycaemia in Asian subjects In case of missed dose take as soon as possible novo nordisk

View entire presentation